Investors’ Favour Strengthens Elevance Health’s (ELV) Rebound
Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Elevance Health Inc. (ELV)
Market is closed
Sector: Hospital & Medical Service Plans
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | High Ground Investment Management Edgar Allen | 679,904 | $262,939,273 | +98% | 23.09% |
| 2. | Polaris Capital Management Bernard Horn | 43,824 | $16,948,056 | -39% | 1.6% |
| 3. | Levin Easterly Partners John Murphy | 43,512 | $16,827,396 | +2% | 0.86% |
| 4. | Iridian Asset Management David Cohen And Harold Levy | 14,989 | $5,796,696 | -31% | 1.99% |
| 5. | Lee Munder Capital Group Lee Munder | 4,287 | $1,657,912 | +2% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $366.05 | 1,000 | $366,050.00 | 10,908 | 2026-07-17 | Filing | |
| $368.25 | 2,045 | $753,071.25 | 171,976 | 2026-07-17 | Filing | |
| $366.41 | 680 | $249,158.80 | 169,931 | 2026-07-17 | Filing | |
| $289.84 | 3,000 | $869,520.00 | 3,639 | 2026-03-05 | Filing | |
| $312.15 | 1,200 | $374,580.00 | 3,502 | 2025-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $403.16 | 369 | $148,766.04 | 3,740 | 2026-06-12 | Filing | |
| $401.77 | 151 | $60,667.27 | 10,734 | 2026-06-11 | Filing | |
| $403.13 | 1,531 | $617,192.03 | 4,109 | 2026-05-19 | Filing | |
| $287.50 | 26 | $7,475.00 | 218 | 2026-03-12 | Filing | |
| $284.92 | 3,196 | $910,604.32 | 11,791 | 2026-03-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 737,922 | $285,376,389 | 4.05% | |
| 2. | 571,339 | $220,953,931 | 0.13% | |
| 3. | 508,280 | $196,567,097 | 0.44% | |
| 4. | 461,600 | $178,514,568 | 6.03% | |
| 5. | 441,940 | $171,104,235 | 0.84% |
News See All
Will the Market Recognize the True Potential of Elevance Health (ELV)?
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Equity and Income Fund”. A copy of the letter can be downloaded here.
12 Best Value Stocks to Buy Right Now
On June 26, EY-Parthenon's Greg Daco appeared on CNBC's 'The Exchange' to discuss the economy's standing.
Elevance Health (ELV) Fell Amid Healthcare Sector Downturn
Heartland Advisors, an investment management company, released its first-quarter 2026 investor letter for the “Heartland Opportunistic Value Equity Strategy”.
Forget AI: Legendary Value Investor Seth Klarman Is Buying These 10 Value Stocks in 2026
Seth Klarman is one of the legendary value investors of his generation.
The Week That Was, The Week Ahead: Macro and Markets, June 7
Stocks ended the week sharply lower as a stronger-than-expected May jobs report pushed bond yields higher and hit the market’s biggest winners. The...
12 Best Undervalued Stocks to Buy According to the Financial Media
Goldman Sachs Research lifted the forecast for the S&P 500 for year-end 2026 to 8,000, an increase from 7,600. The firm expects a 6% return as of May 26.
10 Best Blue Chip Stocks to Buy for Your Retirement Portfolio
Investing for retirement is a very different kind of challenge. It takes patience, planning, and the ability to stay steady through uncertainty.
Elevance Health (ELV) Positioned for Long-Term Margin Improvement Amid Medium-Term Challenges
Hotchkis & Wiley, an investment management company, released its first-quarter 2026 investor letter for the “Hotchkis & Wiley Large Cap Fundamental Value Fund.” A copy of the letter can be downloaded...
Jefferies Updates Elevance Health, Inc. (ELV) Forecasts After Deeper Analysis of Exchange Segment Dynamics
TheFly reported on April 20 that Jefferies analyst David Windley revised his outlook on ELV, trimming the firm’s price target to $391 from $395 while maintaining a Buy rating on the stock.
Hedge Fund Resource Center